Asymchem Completes First USFDA Inspection at Tianjin 4 Site
TIANJIN, China, October 29, 2026 Asymchem has successfully completed its first U.S. Food and Drug Administration (USFDA) Pre-Approval Inspection...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
TIANJIN, China, October 29, 2026 Asymchem has successfully completed its first U.S. Food and Drug Administration (USFDA) Pre-Approval Inspection...
REDWOOD CITY, Calif. — September 28, 2026 Codexis, Inc. announced an agreement with a pioneering siRNA drug innovator to...
Shanghai, China, August 12, 2026 Aurisco Pharmaceutical announced that its manufacturing site in Yangzhou, China, has successfully passed a...
